OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) Files An 8-K Other Events
Item 8.01 Other Events
On March 19, 2019, OncBioMune Pharmaceuticals, Inc. issued a press release announcing they have received notification from Dana-Farber/Harvard Cancer Center that its Phase 2 clinical trial of ProscaVax, a PSA/IL-2/GM-CSF vaccine, in treatment-nave patients with clinically localized prostate cancer being conducted by Beth Israel Deaconess Medical Center (BIDMC) is officially activated and recruiting patients. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press Release of OncBioMune Pharmaceuticals, Inc., dated as of March 19, 2019. |
OncBioMune Pharmaceuticals, Inc Exhibit
EX-99.1 2 ex99-1.htm Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment BATON ROUGE,…
To view the full exhibit click here
About OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP)
OncBioMune Pharmaceuticals, Inc., formerly Quint Media Inc., is a biotechnology company. The Company specializes in various cancer therapies. The Company focuses on developing breast and prostate cancer therapeutic vaccines, and a process for the growth of cancer cells and targeted chemotherapies. The Company’s vaccine technology is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The Company’s product portfolio consists of approximately three target therapies and a vaccine platform that allows creation of a therapeutic vaccine for various solid tumor cancer. The Company’s lead product, ProscaVax is indicated for prostate cancer. The Company focuses on planning Phase II clinical trials of ProscaVax. The Company is also focused on development of its other technologies, such as the paclitaxel-albumin conjugate. It also has a portfolio of targeted therapies, some of which are biosimilars to drugs, including paclitaxel (Abraxane).
